Want to see SG:1B1 full AI Analyst Report?
1B1 Stock Chart & Stats
S$0.36
S$0.00(0.00%)
At close: 4:00 PM EST
S$0.36
S$0.00(0.00%)
Day’s Range― - ―
52-Week RangeS$0.29 - S$0.40
Previous CloseN/A
Volume0.00
Average Volume (3M)50.29K
Market Cap
S$57.68M
Enterprise ValueS$55.97M
Total Cash (Recent Filing)S$6.96M
Total Debt (Recent Filing)S$2.40M
Price to Earnings (P/E)11.4
Beta0.17
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.37%
Share Statistics
EPS (TTM)0.07
Shares Outstanding156,309,900
10 Day Avg. Volume16,820
30 Day Avg. Volume50,290
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.09
Price to Sales (P/S)2.29
P/FCF Ratio6.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High And Sustainable MarginsVery high gross and recent operating/net margins indicate durable unit economics and pricing power in the core diagnostic business. Such margin headroom supports reinvestment, dividend capacity, and resilience to cost shocks even if revenue growth is muted, preserving long-term cash profitability.
Material Deleveraging And Strong Balance SheetMeaningful reduction in leverage and rising equity strengthen financial flexibility and lower refinancing risk. A de-risked capital structure supports opportunistic investments, dividend sustainability, and downside protection during sector cycles, improving long-term solvency.
Solid Cash Generation And ConversionHigh conversion of net income into free cash flow shows efficient working capital and cash discipline. Even with volatile growth, reliable cash generation sustains operations, funds dividends, and enables selective capital allocation, underpinning durable shareholder support.
Bears Say
Sharply Negative Revenue GrowthPersistent and recent sharp revenue declines undermine long-term scalability of the business model. Even with strong margins, falling top line limits absolute profit growth, compresses future cash generation potential, and increases sensitivity to pricing and demand shifts.
Weak Free Cash Flow MomentumNegative FCF growth despite good conversion ratios signals deteriorating operational scale or one-off drains. Continued FCF contraction could constrain reinvestment, capex flexibility, and dividend sustainability, raising medium-term funding and strategic risk.
Earnings Consistency / ROE VolatilityVolatile ROE implies earnings are cyclical or impacted by inconsistent revenue drivers. This variability reduces predictability of shareholder returns and complicates planning for capital allocation, making long-term performance less certain despite current high ROE.
HC Surgical Specialists Ltd News
1B1 FAQ
What was HC Surgical Specialists Ltd’s price range in the past 12 months?
HC Surgical Specialists Ltd lowest share price was S$0.29 and its highest was S$0.40 in the past 12 months.
What is HC Surgical Specialists Ltd’s market cap?
HC Surgical Specialists Ltd’s market cap is S$57.68M.
When is HC Surgical Specialists Ltd’s upcoming earnings report date?
HC Surgical Specialists Ltd’s upcoming earnings report date is Jul 23, 2026 which is in 22 days.
How were HC Surgical Specialists Ltd’s earnings last quarter?
HC Surgical Specialists Ltd released its earnings results on Jan 13, 2026. The company reported S$0.026 earnings per share for the quarter, beating the consensus estimate of N/A by S$0.026.
Is HC Surgical Specialists Ltd overvalued?
According to Wall Street analysts HC Surgical Specialists Ltd’s price is currently Overvalued.
Does HC Surgical Specialists Ltd pay dividends?
HC Surgical Specialists Ltd pays a Notavailable dividend of S$0.009 which represents an annual dividend yield of 3.37%. See more information on HC Surgical Specialists Ltd dividends here
What is HC Surgical Specialists Ltd’s EPS estimate?
HC Surgical Specialists Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HC Surgical Specialists Ltd have?
HC Surgical Specialists Ltd has 156,309,900 shares outstanding.
What happened to HC Surgical Specialists Ltd’s price movement after its last earnings report?
HC Surgical Specialists Ltd reported an EPS of S$0.026 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.571%.
Which hedge fund is a major shareholder of HC Surgical Specialists Ltd?
Currently, no hedge funds are holding shares in SG:1B1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HC Surgical Specialists Ltd
HC Surgical Specialists Limited, an investment holding company, primarily delivers a diverse spectrum of medical services across Singapore. Through its network of clinics, the company specializes in endoscopic procedures, such as gastroscopies and colonoscopies, in addition to providing general surgical services with a notable focus on colorectal issues. Their expertise further extends to treating a variety of conditions, including haemorrhoids, anal fissures, hernias, anal abscesses, cholecystitis, anal fistulas, appendicitis, colorectal and gastric cancers, lipomas, and cysts, utilizing advanced techniques like vein laser vascular therapy and laparoscopy. Moreover, the company offers extensive orthopedic services. These address concerns such as joint pain, sports injuries, osteoarthritis, rotator cuff tears, trigger finger, tenosynovitis, tunnel syndrome, and various wounds or lumps. Surgical interventions include joint replacements, arthroscopic procedures, knee osteotomy, realignment surgery, endoscopic spine surgery, disc replacements, spinal decompression, and fracture management, supported by orthobiologic injections. Beyond clinical care, the company provides comprehensive home care services, encompassing medical, nursing, physiotherapy, speech, occupational therapy, and ambulance support. Their community health initiatives include health screenings, management of acute and chronic conditions, pre-employment check-ups, and participation in public health schemes such as the 'swab and send home' program, the community health assist scheme, and COVID-19 testing. To support accurate diagnosis, a full array of diagnostic tests is available, including blood work, X-rays, ultrasounds, CT scans, and MRIs. The company was founded in Singapore in 2015, where it continues to be headquartered.
Technical Analysis
Hyphens Pharma International Ltd.
―
Medtecs International Corporation Ltd.
―
UG Healthcare Corp. Ltd.
―
Alliance Healthcare Group Ltd.
―
Medinex Ltd.
―






